AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16918658 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% levobupivacaine
Number of subjects: 86
Study 16918658 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% bupivacaine
Number of subjects: 86
Study 16918658 — intervention group
Group type: COMPARATOR
Intervention: 0.2% ropivacaine
Number of subjects: 86
Study 15191587 — intervention group
Group type: EXPERIMENTAL
Intervention: IMZ implant system (two-stage cylinder type)
Number of subjects: 30
Study 15191587 — intervention group
Group type: EXPERIMENTAL
Intervention: Brånemark implant system (two-stage screw type)
Number of subjects: 30
Study 15191587 — intervention group
Group type: EXPERIMENTAL
Intervention: ITI implant system (one-stage screw type)
Number of subjects: 30
Study 10775816 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐emptive therapy with ganciclovir
Number of subjects: 19
Study 10775816 — intervention group
Group type: COMPARATOR
Intervention: Universal prophylaxis with ganciclovir (historical controls)
Number of subjects: 19
Study 9185458 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 (0.02 microgram kg‐1 min‐1)
Number of subjects: 109
Study 9185458 — intervention group
Group type: COMPARATOR
Intervention: Control (standard lidocaine infusion)
Number of subjects: 109
Study 8454792 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom diary monitoring
Number of subjects: 40
Study 8454792 — intervention group
Group type: COMPARATOR
Intervention: PEFR monitoring
Number of subjects: 40
Study 3948546 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen therapy to raise PaO2 ≥ 60 mm Hg (group 1, n = 6)
Number of subjects: 12
Study 3948546 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen therapy to raise PvO2 ≥ 36 mm Hg (group 2, n = 6)
Number of subjects: 12
Study 31053468 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive direct anterior approach (MIDA)
Number of subjects: 164
Study 31053468 — intervention group
Group type: COMPARATOR
Intervention: Direct lateral approach (DLA)
Number of subjects: 164
Study 28295425 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of atropine administered before deflation of the cryoballoon (trial group)
Number of subjects: 25
Study 28295425 — intervention group
Group type: COMPARATOR
Intervention: Atropine administered after the onset of hemodynamic variation (control group)
Number of subjects: 25
Study 28295425 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic atropine administration
Number of subjects: 25
Study 25201758 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (patients chose route of administration)
Number of subjects: 307
Study 25201758 — intervention group
Group type: COMPARATOR
Intervention: Control group (physician decided route of administration)
Number of subjects: 307
Study 25201758 — intervention group
Group type: COMPARATOR
Intervention: Control group (sublingual immunotherapy)
Number of subjects: 307
Study 23684449 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100mg)
Number of subjects: 50
Study 21411832 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg caffeine
Number of subjects: 15
Study 21411832 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg caffeine
Number of subjects: 15
Study 21411832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 19427990 — intervention group
Group type: EXPERIMENTAL
Intervention: AquaLase
Number of subjects: 50
Study 19427990 — intervention group
Group type: COMPARATOR
Intervention: NeoSoniX
Number of subjects: 50
Study 16522922 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-fortified milk
Number of subjects: 501
Study 16522922 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D-fortified milk
Number of subjects: 501
Study 16522922 — intervention group
Group type: COMPARATOR
Intervention: Control group (no milk supplementation)
Number of subjects: 501
Study 14680564 — intervention group
Group type: EXPERIMENTAL
Intervention: DTI navigation
Number of subjects: 49
Study 14680564 — intervention group
Group type: COMPARATOR
Intervention: Traditional navigation
Number of subjects: 49
Study 11385214 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler sonography
Number of subjects: 158
Study 11385214 — intervention group
Group type: COMPARATOR
Intervention: Selective intra-arterial angiography
Number of subjects: 158
Study 9726671 — intervention group
Group type: EXPERIMENTAL
Intervention: Aciclovir (Zovirax) combined with prednisolone
Number of subjects: 44
Study 9726671 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone alone (Control)
Number of subjects: 44
Study 8067760 — intervention group
Group type: EXPERIMENTAL
Intervention: LY217896 (75 mg) once daily for 7 days
Number of subjects: 0
Study 8067760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3056132 — intervention group
Group type: EXPERIMENTAL
Intervention: External cardiac pacing device
Number of subjects: 239
Study 3056132 — intervention group
Group type: COMPARATOR
Intervention: Not paced (Control)
Number of subjects: 239
Study 3056132 — intervention group
Group type: EXPERIMENTAL
Intervention: External cardiac pacing device (in hypotensive bradycardia)
Number of subjects: 239
Study 3056132 — intervention group
Group type: COMPARATOR
Intervention: Not paced (Control) (in hypotensive bradycardia)
Number of subjects: 239
Study 30583148 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine 40 mg/day
Number of subjects: 191
Study 30583148 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine 80 mg/day
Number of subjects: 191
Study 30583148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 30583148 — intervention group
Group type: COMPARATOR
Intervention: Valbenazine and placebo
Number of subjects: 191
Study 28291393 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD + INRT for ePET-positive patients
Number of subjects: 1950
Study 28291393 — intervention group
Group type: COMPARATOR
Intervention: ABVD only for ePET-negative patients in the F group
Number of subjects: 1950
Study 28291393 — intervention group
Group type: COMPARATOR
Intervention: ABVD only for ePET-negative patients in the U group
Number of subjects: 1950
Study 25624754 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI-based cognitive training (CT) program, 24 half-hour sessions over 8 weeks
Number of subjects: 39
Study 25624754 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (no intervention for 8 weeks)
Number of subjects: 39
Study 25624754 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI-based cognitive training (CT) program
Number of subjects: 39
Study 23445135 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal lactoferrin for 21 days
Number of subjects: 128
Study 23445135 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 128
Study 21333873 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcoaxial cataract surgery (1.8 mm CCI)
Number of subjects: 2
Study 21333873 — intervention group
Group type: COMPARATOR
Intervention: Biaxial cataract surgery (1.2 to 1.4 mm trapezoidal CCI)
Number of subjects: 2
Study 19847073 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training (e.g. memory skills training, imagery, method of loci)
Number of subjects: 24
Study 19847073 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 24
Study 19847073 — intervention group
Group type: COMPARATOR
Intervention: Active control conditions
Number of subjects: 24
Study 16364599 — intervention group
Group type: EXPERIMENTAL
Intervention: BP230 ELISA
Number of subjects: 239
Study 16364599 — intervention group
Group type: EXPERIMENTAL
Intervention: BP180 ELISA
Number of subjects: 239
Study 16364599 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined BP230 and BP180 ELISA
Number of subjects: 239
Study 15715291 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9890849 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide gas at graded concentrations (n = 8)
Number of subjects: 16
Study 9890849 — intervention group
Group type: COMPARATOR
Intervention: Intravenous isosorbide dinitrate, 2.5 mg (n = 8)
Number of subjects: 16
Study 8886349 — intervention group
Group type: EXPERIMENTAL
Intervention: Undernourished individuals
Number of subjects: 3200
Study 8886349 — intervention group
Group type: COMPARATOR
Intervention: Adequately nourished individuals
Number of subjects: 3200
Study 8886349 — intervention group
Group type: EXPERIMENTAL
Intervention: Undernourished individuals with acceptable serum vitamin A levels
Number of subjects: 3200
Study 8886349 — intervention group
Group type: COMPARATOR
Intervention: Adequately nourished individuals with acceptable serum vitamin A levels
Number of subjects: 3200
Study 8886349 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-anemic individuals
Number of subjects: 3200
Study 8886349 — intervention group
Group type: EXPERIMENTAL
Intervention: Goitrous subjects
Number of subjects: 3200
Study 8886349 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-goitrous subjects
Number of subjects: 3200
Study 8886349 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A deficient subjects
Number of subjects: 3200
Study 8886349 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-vitamin A deficient subjects
Number of subjects: 3200
Study 1852567 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermapoints Massageroller
Number of subjects: 0
Study 1852567 — intervention group
Group type: COMPARATOR
Intervention: Active placebo massage
Number of subjects: 0
Study 6367012 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective gastric vagotomy (SGV)
Number of subjects: 685
Study 6367012 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PCV)
Number of subjects: 685
Study 6367012 — intervention group
Group type: EXPERIMENTAL
Intervention: Less than 20% initial reduction in PAOpg (SGV and PCV)
Number of subjects: 685
Study 6367012 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 685
Study 31964174 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent rehabilitation program (motivational interview, goal attainment process, guidance for safe walking, progressive home exercise program, physical activity counseling, standard care)
Number of subjects: 117
Study 31964174 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 117
Study 31964174 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent rehabilitation program
Number of subjects: 117
Study 31250193 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading (group A, n=81)
Number of subjects: 158
Study 31250193 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed loading (group B, n=78)
Number of subjects: 158
Study 31065710 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial brooding temperature at 36°C
Number of subjects: 360
Study 31065710 — intervention group
Group type: COMPARATOR
Intervention: Initial brooding temperatures at 26, 28, 30, and 32°C
Number of subjects: 360
Study 31065710 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial brooding temperatures at 26 or 36°C
Number of subjects: 360
Study 31065710 — intervention group
Group type: COMPARATOR
Intervention: Initial brooding temperatures at 28 to 34°C
Number of subjects: 360
Study 31065710 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper critical temperature for initial brooding
Number of subjects: 360
Study 28301690 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG-10 (10 mg/kg)
Number of subjects: 224
Study 28301690 — intervention group
Group type: COMPARATOR
Intervention: ATG-6 (6 mg/kg)
Number of subjects: 224
Study 25441486 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day soy isoflavone supplementation
Number of subjects: 190
Study 25441486 — intervention group
Group type: COMPARATOR
Intervention: 500 mg calcium carbonate (Control)
Number of subjects: 190
Study 23064969 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive adaptation training (CAT); specific adjustments made for Danish context, duration not specified.
Number of subjects: 0
Study 21712524 — intervention group
Group type: EXPERIMENTAL
Intervention: Early PCI
Number of subjects: 197
Study 21712524 — intervention group
Group type: COMPARATOR
Intervention: Delayed PCI
Number of subjects: 197
Study 18663579 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedles (180 mum height)
Number of subjects: 12
Study 18663579 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedles (280 mum height)
Number of subjects: 12
Study 18663579 — intervention group
Group type: COMPARATOR
Intervention: Hypodermic needle (25‐G)
Number of subjects: 12
Study 18663579 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedles (180 mum height) and (280 mum height)
Number of subjects: 12
Study 16551310 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased fluid intake by 1.5 L of water
Number of subjects: 141
Study 16551310 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication (8 mL inactive syrup per day)
Number of subjects: 141
Study 15621108 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple dosing of basiliximab (3 doses: prior to transplantation, day 4, and day 21)
Number of subjects: 11
Study 15621108 — intervention group
Group type: COMPARATOR
Intervention: Two doses of basiliximab (prior to transplantation and day 4)
Number of subjects: 11
Study 10752804 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) 25 mg and glucose 5 g administered simultaneously
Number of subjects: 12
Study 10752804 — intervention group
Group type: COMPARATOR
Intervention: Control group (AMI patients)
Number of subjects: 12
Study 8883420 — intervention group
Group type: EXPERIMENTAL
Intervention: STn linked to KLH with DETOX-B adjuvant, 100 micrograms, subcutaneous injection at weeks 0, 2, 5, and 9, with low-dose cyclophosphamide (CTX, 300 mg m-2) pretreatment.
Number of subjects: 23
Study 8883420 — intervention group
Group type: COMPARATOR
Intervention: STn linked to KLH with DETOX-B adjuvant, 100 micrograms, subcutaneous injection at weeks 0, 2, 5, and 9, without low-dose cyclophosphamide (CTX, 300 mg m-2) pretreatment.
Number of subjects: 23
Study 1294055 — intervention group
Group type: EXPERIMENTAL
Intervention: Coumarin (5,6 benzo‐[alpha]‐pyrone, 56 BaP) and oxerutins (HR, O(beta‐hydroxy‐ethyl)‐rutosides)
Number of subjects: 0
Study 1294055 — intervention group
Group type: EXPERIMENTAL
Intervention: Coumarin and oxerutins
Number of subjects: 0
Study 6374537 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens 0.625 mg per day
Number of subjects: 0
Study 6374537 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens 1.25 mg per day
Number of subjects: 0
Study 6374537 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens <0.625 mg per day
Number of subjects: 0
Study 6374537 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (general)
Number of subjects: 0
Study 6374537 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens
Number of subjects: 0
Study 3578861 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 57
Study 3578861 — intervention group
Group type: COMPARATOR
Intervention: Halothane anesthesia
Number of subjects: 57
Study 29471904 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) for 6 months with pyridoxine
Number of subjects: 1284
Study 29471904 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT)
Number of subjects: 1284
Study 27166229 — intervention group
Group type: EXPERIMENTAL
Intervention: SWS disruption (auditory stimuli causing SWS fragmentation)
Number of subjects: 14
Study 27166229 — intervention group
Group type: EXPERIMENTAL
Intervention: SWS disruption
Number of subjects: 14
Study 24864327 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractive Sulcoflex 653F (35 eyes)
Number of subjects: 68
Study 24864327 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffractive MS 714 PB Diff (33 eyes)
Number of subjects: 68
Study 23690364 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in infant nutrition guidelines for health care workers
Number of subjects: 458
Study 23690364 — intervention group
Group type: COMPARATOR
Intervention: Usual practices control group
Number of subjects: 458
Study 20142635 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 27
Study 19128642 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program (Cawthorne-Cooksey exercises, six times/day for 4 weeks)
Number of subjects: 38
Study 19128642 — intervention group
Group type: COMPARATOR
Intervention: Betahistine (24 mg/d for 1 month)
Number of subjects: 38
Study 19128642 — intervention group
Group type: COMPARATOR
Intervention: Comparison between exercise and medication groups
Number of subjects: 38
Study 15871016 — intervention group
Group type: EXPERIMENTAL
Intervention: (131)I plus lithium (group I+L)
Number of subjects: 80
Study 15871016 — intervention group
Group type: COMPARATOR
Intervention: (131)I alone (group I)
Number of subjects: 80
Study 15871016 — intervention group
Group type: EXPERIMENTAL
Intervention: (131)I
Number of subjects: 80
Study 12836801 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 30
Study 12836801 — intervention group
Group type: COMPARATOR
Intervention: Educational Treatment (ET)
Number of subjects: 30
Study 10567627 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg salmeterol + 600 microg oxitropium bromide
Number of subjects: 32
Study 10567627 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg salmeterol + placebo
Number of subjects: 32
Study 10567627 — intervention group
Group type: COMPARATOR
Intervention: placebo + 600 microg oxitropium bromide
Number of subjects: 32
Study 10567627 — intervention group
Group type: COMPARATOR
Intervention: placebo + placebo
Number of subjects: 32
Study 8881455 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with TPO‐Ab positivity (n = 50)
Number of subjects: 3756
Study 8881455 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with low serum TSH (< 0.4 mU/l) (n = 44)
Number of subjects: 3756
Study 8881455 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with TSH > 4.0 mU/l (n = 44)
Number of subjects: 3756
Study 8881455 — intervention group
Group type: COMPARATOR
Intervention: Patients without thyroid abnormalities (n = 83)
Number of subjects: 3756
Study 1810019 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 1000 mg daily for 4 days
Number of subjects: 8
Study 6835734 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 28
Study 6835734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31250540 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 IU/d vitamin D
Number of subjects: 84
Study 31250540 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000 IU/d vitamin D
Number of subjects: 84
Study 29210505 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiolabeled albumin applied to the nasal mucosa in CF patients
Number of subjects: 18
Study 29210505 — intervention group
Group type: COMPARATOR
Intervention: Radiolabeled albumin applied to the nasal mucosa in controls
Number of subjects: 18
Study 27387457 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational interventions during prenatal care
Number of subjects: 901
Study 27387457 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure-based education provided in the hospital when the baby is born
Number of subjects: 901
Study 24694082 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video games intervention
Number of subjects: 322
Study 22526478 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (RAE)
Number of subjects: 37
Study 22526478 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control (RAC)
Number of subjects: 37
Study 20506403 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Number of subjects: 356
Study 20506403 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Number of subjects: 356
Study 20506403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study 17825130 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg/day for Week 1 followed by 20 mg/day thereafter)
Number of subjects: 329
Study 17825130 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (after randomization)
Number of subjects: 329
Study 15741841 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g.min of maltodextrin + 0.6 g.min of fructose (MD+F)
Number of subjects: 8
Study 15741841 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g.min of maltodextrin (MD)
Number of subjects: 8
Study 15741841 — intervention group
Group type: COMPARATOR
Intervention: Plain water (control)
Number of subjects: 8
Study 11316178 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 34
Study 11316178 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (norfloxacin and neomycin)
Number of subjects: 34
Study 11316178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 9141939 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental 4 mg/kg
Number of subjects: 40
Study 9141939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1.5 mg/kg
Number of subjects: 40
Study 8161723 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration (CVVH)
Number of subjects: 22
Study 8161723 — intervention group
Group type: COMPARATOR
Intervention: Intermittent hemodialysis (IHD)
Number of subjects: 22
Study 8161723 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVH
Number of subjects: 22
Study 8161723 — intervention group
Group type: COMPARATOR
Intervention: IHD
Number of subjects: 22
Study 2834601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2834601 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (50 mg)
Number of subjects: 9
Study 2834601 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (10 mg)
Number of subjects: 9
Study 2834601 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 9
Study 30729953 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin infusion at 3 μg/kg/h, halved after arterial anastomosis and continued for 3 days
Number of subjects: 86
Study 30729953 — intervention group
Group type: COMPARATOR
Intervention: Control group (no terlipressin infusion)
Number of subjects: 86
Study 28076335 — intervention group
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Number of subjects: 1733